CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 50 enrolled
Drug / intervention
Litramine +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01505387
NCT01505387Phase 4Completed

Double-blind, Randomized, Placebo-controlled Clinical Investigation to Evaluate the Safety and Efficacy of Litramine in Maintaining Body Weight Loss in Overweight and Obese Subjects

InQpharm Group·interventional·Posted Jan 6, 2012·Updated Jun 1, 2015

In Brief

A Phase 4 clinical trial evaluating Litramine and Placebo for Weight Maintenance and 2 related conditions. Completed, enrolled 50 participants across 1 site.

Detailed Summary

The effect of Litramine on weight loss has previously been studied during a 12-week intervention period with promising results. The present study looks into the effect of weight maintenance using Litramine following initial weight loss, for a longer period of 24 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 6, 2012
Enrollment StartJan 1, 2012
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.5 years ago

Interventions

Litraminedietary

Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)

Placebodietary

Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)